CAH Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 0.72% compared to Cardinal Health's net margin of 12.41%. Cardinal Health's return on equity of -- beat Boston Scientific's return on equity of 8.96%.

Cardinal Health has a consensus price target of $142.21, signalling upside risk potential of 7.92%. On the other hand Boston Scientific has an analysts' consensus of $115.00 which suggests that it could grow by 22.77%. Given that Boston Scientific has higher upside potential than Cardinal Health, analysts believe Boston Scientific is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.612, which suggesting that the stock is 38.803% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.54%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $55.3B, which are larger than Boston Scientific quarterly revenues of $4.6B. Cardinal Health's net income of $400M is lower than Boston Scientific's net income of $566M. Notably, Cardinal Health's price-to-earnings ratio is 24.58x while Boston Scientific's PE ratio is 74.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.15x versus 8.31x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Cencora has a net margin of 0.72% compared to Cardinal Health's net margin of 0.6%. Cardinal Health's return on equity of -- beat Cencora's return on equity of 155.22%.

Cardinal Health has a consensus price target of $142.21, signalling upside risk potential of 7.92%. On the other hand Cencora has an analysts' consensus of $287.49 which suggests that it could grow by 1.11%. Given that Cardinal Health has higher upside potential than Cencora, analysts believe Cardinal Health is more attractive than Cencora.

Cardinal Health has a beta of 0.612, which suggesting that the stock is 38.803% less volatile than S&P 500. In comparison Cencora has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.294%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.54%. Cencora offers a yield of 0.75% to investors and pays a quarterly dividend of $0.55 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $55.3B, which are smaller than Cencora quarterly revenues of $81.5B. Cardinal Health's net income of $400M is lower than Cencora's net income of $488.6M. Notably, Cardinal Health's price-to-earnings ratio is 24.58x while Cencora's PE ratio is 40.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.15x versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 0.72% compared to Cardinal Health's net margin of -58.2%. Cardinal Health's return on equity of -- beat Masimo's return on equity of -23.05%.

Cardinal Health has a consensus price target of $142.21, signalling upside risk potential of 7.92%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 27.16%. Given that Masimo has higher upside potential than Cardinal Health, analysts believe Masimo is more attractive than Cardinal Health.

Cardinal Health has a beta of 0.612, which suggesting that the stock is 38.803% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.54%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardinal Health pays 58.57% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $55.3B, which are larger than Masimo quarterly revenues of $600.7M. Cardinal Health's net income of $400M is higher than Masimo's net income of -$349.6M. Notably, Cardinal Health's price-to-earnings ratio is 24.58x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.15x versus 3.98x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

McKesson has a net margin of 0.72% compared to Cardinal Health's net margin of 0.92%. Cardinal Health's return on equity of -- beat McKesson's return on equity of --.

Cardinal Health has a consensus price target of $142.21, signalling upside risk potential of 7.92%. On the other hand McKesson has an analysts' consensus of $693.18 which suggests that it could grow by 0.55%. Given that Cardinal Health has higher upside potential than McKesson, analysts believe Cardinal Health is more attractive than McKesson.

Cardinal Health has a beta of 0.612, which suggesting that the stock is 38.803% less volatile than S&P 500. In comparison McKesson has a beta of 0.494, suggesting its less volatile than the S&P 500 by 50.561%.

Cardinal Health has a quarterly dividend of $0.51 per share corresponding to a yield of 1.54%. McKesson offers a yield of 0.4% to investors and pays a quarterly dividend of $0.71 per share. Cardinal Health pays 58.57% of its earnings as a dividend. McKesson pays out 10.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Cardinal Health quarterly revenues are $55.3B, which are smaller than McKesson quarterly revenues of $95.3B. Cardinal Health's net income of $400M is lower than McKesson's net income of $879M. Notably, Cardinal Health's price-to-earnings ratio is 24.58x while McKesson's PE ratio is 31.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardinal Health is 0.15x versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.